No matches
Dermatology

Global ADVENT FORUM 2023, Dermatology Section | Madrid

New expert presentations from the 2023 ADVENT FORUM, Dermatology section, where the global faculty discuss itch as the common thread in dermatological type 2 inflammation, the evolving concept of disease modification in atopic dermatitis, and the latest updates in prurigo nodularis and chronic spontaneous urticaria.
Amy Paller
Thomas Casale
Stephan Weidinger
MD, MS
Amy Paller +5 more
See post-event materials
.
Past event
1December2023

Symposium Details

December 1

Global ADVENT FORUM 2023, Dermatology Plenary 1: Itch: The Common Thread in Dermatological Type 2 Inflammation (AD, PN, & CSU)​

A review of the shared and unique neuroimmune mechanisms in the generation of itch across AD, PN, and CSU.

December 1

Global ADVENT FORUM 2023, Dermatology Plenary 2: New Perspectives on Disease Modification in Atopic Dermatitis

An exploration into the concept and potential of disease modification through therapeutic interventions in AD.

December 1

Global ADVENT FORUM 2023, Dermatology Plenary 3: Updates in PN and CSU: Emerging Therapeutic Landscapes and Implications for Patient Management

A review of disease burden and treatment needs in PN and CSU, and how current and emerging therapies can impact patient management in these respective diseases.

Learning objectives

  • Discuss the pathophysiological processes mediating pruritus in AD, PN, and CSU​
  • Describe how type 2 inflammatory cytokines are involved in inducing and amplifying pruritus in AD, PN, and CSU​
  • Explore the shared and distinct mechanisms of pruritus in AD, PN, and CSU​
  • Explore the concept of disease modification in the context of AD
  • Review existing data on disease control with therapeutic interventions and discuss the markers that could be used to define deep remission in AD
  • Discuss perspectives for reducing the development of ​new or worsening future atopic comorbidities​
  • Describe the wide-ranging disease burden of PN and CSU, and discuss how this impacts patient quality of life and treatment needs
  • Review current unmet needs in PN and CSU management
  • Describe the evolving therapeutic landscape in PN and CSU, considering data for approved treatments and ongoing clinical trials, and discuss potential impacts on patient management in the respective therapeutic areas
Tags
biologicsbiomarkerscoexisting diseasescytokinesdisease controldisease progressionguidelinesitchmechanism of diseaseneuroimmune mechanismsquality of liferemissiontype 2 inflammation
MAT-GLB-2306039 V2 10/2024

Speakers

Dermatology
MD, MS

Amy Paller

Walter J. Hamlin Professor and Chair of Dermatology; Professor of Pediatrics at Northwestern University, Evanston, Illinois, US

Allergy/Immunology
MD

Thomas Casale

Professor of Medicine and Pediatrics; Chief of Clinical and Translational Research, University of South Florida, Tampa, United States

Dermatology
MD, PhD

Stephan Weidinger

Professor and Chair for Dermatology at the Christian-Albrechts-University; Director of the Department of Dermatology and Allergy at the University Hospital Schleswig-Holstein, Campus Kiel, Germany

Dermatology
MD

Eric Simpson

Professor of Dermatology, School of Medicine, Oregon Health & Science University, Portland, US

Dermatology
MD, PhD, MSCI

Raj Chovatiya

Assistant Professor of Dermatology at the Northwestern University Feinberg School of Medicine in Chicago, US

Dermatology
MD

Michele Ramien

Clinician-Investigator at the Alberta Children’s Hospital in Calgary, Alberta, Canada

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: MacauChange country/region